Unitree Robotics (688836.SH) - IPO Analysis

Unitree Robotics (688836.SH), the first pure-play humanoid robotics company to list in mainland China, debuted on the STAR Market on 19 August and immediately became the most expensive robot stock on earth. Shares opened 629% above the 150.8 yuan offer price at 1,100 yuan, putting the company at roughly RMB 445 billion (~US$66 billion), and closed the session up about 460%. The business is genuinely impressive: profitable, hypergrowing, and shipping more humanoids than anyone else. The price is the problem. At the close, Unitree traded at roughly 1,200x trailing earnings. Here is the scorecard, the math, and why we are not buyers.

At a Glance

• Listing: 19 August 2026, Shanghai STAR Market (688836.SH); raised RMB 6.1B (~US$905M) at 150.8 yuan, 10% of post-offer capital
• Debut: opened at 1,100 yuan (+629%); closed ~845 yuan (+460%); market cap ~RMB 342B (~US$50B) at the close
• 2025 financials: revenue RMB 1.7B (+332%), net profit ~RMB 280M (~US$41M); H1 2026 revenue RMB 1.15B (+48.5%)
• Scale: 5,500+ humanoid robots shipped in 2025, the most of any maker globally
• Valuation at close: ~1,200x trailing earnings, ~200x trailing sales
• Pre-IPO context: crypto perps implied ~US$38B before the listing; the public market opened above even that

The Debut

Unitree opened 629% higher at 1,100 yuan, a per-lot gain of roughly RMB 475,000, taking the market cap to RMB 444.9 billion (~US$66 billion) at the open. The stock then drifted and closed near 845 yuan, still up 460%. The offering, backed among others by DeepSeek and a state oil giant, was massively oversubscribed. Even the crypto market got left behind: perpetual futures on Hyperliquid had priced Unitree near US$38 billion before the listing, more than four times the ~US$9 billion bankers' valuation, and Shanghai opened roughly 75% above even that implied price.

The Business

Unitree sells quadruped robots (Go2) and humanoids (H1, G1, R1) with motors, joints and controllers built largely in-house, the vertical integration behind its aggressive pricing. The R1 humanoid now starts at RMB 26,900, down from a 2023 average of roughly RMB 593,000, a ~95% price collapse in three years. Humanoids were 51.5% of revenue in the first nine months of 2025, up from 27.6% in 2024, at a ~63% gross margin; the core business runs at ~60%. Unlike virtually every rival (Tesla's Optimus is pre-revenue, Figure and Agility are venture-funded, UBTech still loses money), Unitree is profitable.

Valuation: The Price Is the Risk

At the close, Unitree was worth roughly RMB 342 billion (~US$50 billion): ~200x trailing sales and ~1,200x trailing earnings. For perspective, Goldman Sachs puts the entire global humanoid market at around US$38 billion in annual value by 2035. Unitree alone opened above that number on debut day. Even the crypto market's aggressive ~US$38 billion pre-IPO estimate looked cheap an hour into the session.

We are not saying the company is bad; we are saying the price demands years of near-perfect execution. The pattern for hot A-share debuts is froth, give-back, then a base. Lock-up expiries (12 months for most pre-IPO holders, 36 for the founder) will feed supply over the next year, and a 60% gross margin in contested hardware is less a moat than a flare for competitors: Unitree's own humanoid prices have already fallen ~95% in three years while unit costs barely moved. If margins mean-revert, the market re-rates the stock from tech to manufacturer, which typically erases more value than the margin drop itself.

Our Take

We are not buying, and Unitree is not going on our watchlist; we will only revisit the stock after a serious derating. That derating is already underway: in the ten days since the debut, the stock has experienced the expected give-back, sliding to around 585 yuan by August 30, down roughly 30% from its first-day close and nearly 50% from the opening bell high of 1,100 yuan. We already own this theme at a saner price: UBTech Robotics (9880.HK), where we hold a small remaining position after trimming with realized gains in July. UBTech fell on the day of the debut as attention rotated to Unitree. We kept our small UBTech position and stood on the sidelines. We are still watching for now and have not added. Unitree may well be the better company, but at ~1,200x trailing earnings the price has detached from the cash flows. Geopolitics will swing these stocks: Unitree was added to the US DoD's Section 1260H list in June 2026, and US-China tension will keep producing headlines. Over a three-to-five-year horizon, it is the business that pays, not the headlines. The business here is excellent; the price is not.

Verdict: Pass. Unitree is not on our watchlist; we only revisit after a serious derating. If we want the theme, we buy UBTech (9880.HK) on weakness.

Risks

• Valuation: ~1,200x trailing earnings; anything short of flawless execution punishes the stock.
• Margin reversion: 60% gross margins invite competition; ASPs already fell ~95% in three years.
• Customer mix: more than 70% of humanoid revenue comes from research and education, a pool of maybe 10,000 units a year worldwide.
• Lock-up supply: 12-month and 36-month expiries still ahead.
• Geopolitics: US DoD Section 1260H designation (June 2026) and broader US-China decoupling headlines.